Actively Recruiting
Study of Camrelizumab Plus Apatinib and Chemotherapy in Women With High-risk Gestational Trophoblastic Neoplasia
Led by Peking Union Medical College Hospital · Updated on 2026-11-03
70
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining camrelizumab and apatinib with chemotherapy in patients with ultra high-risk and high-risk chemo-refractory or relapsed gestational trophoblastic neoplasia GTN. This phase 2, open-label study aims to understand how well this combination works and its safety profile in these specific patient groups. Patients in Cohort A will receive camrelizumab intravenously every two weeks, apatinib orally daily, and chemotherapy. After their hormone levels normalize, they will continue with consolidation chemotherapy plus camrelizumab and apatinib, followed by six months of maintenance therapy with camrelizumab and apatinib. Cohort B patients will receive camrelizumab every three weeks, apatinib daily, and chemotherapy chosen by the investigator. Treatment continues until disease progression, unacceptable side effects, or consent withdrawal. Following hormone normalization, Cohort B patients undergo a confirmation period, consolidation therapy, and maintenance treatment similar to Cohort A. Participants will undergo regular evaluations including hormone level monitoring and imaging to assess treatment response and safety. Researchers will measure complete remission rates for Cohort A and objective response rates for Cohort B, along with progression-free survival, overall survival, duration of response, and adverse event frequency. Treatment continues until progression or other reasons, with follow-up extending up to one year to assess outcomes and safety.
CONDITIONS
Brief Title
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
Research Team
Y
Yang Xiang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here